Weave Bio Partners with Takeda to Innovate AI-Driven Regulatory Automation

Weave Bio, a leader in AI-native regulatory automation for drug development, has revealed a collaboration with Takeda aimed at deploying the Weave platform across 14 active programs in various global markets. This partnership merges Weave's AI capabilities with Takeda's regulatory expertise to foster innovation in regulatory workflows.

“Regulatory communications are the most knowledge-intensive workflows in all of drug development, and for too long that knowledge has lived in static documents that are hard to find, cumbersome to manage, and nearly impossible to maintain over time,” stated Brandon Rice, CEO and co-founder of Weave Bio. “Takeda came to this partnership with deep regulatory expertise, pressing needs, and a genuine commitment to collaborative innovation. What we've built together demonstrates how AI-assisted regulatory workflows may evolve across the industry.”

Initially focusing on AI-assisted IND submission preparation, the collaboration has since broadened to include Health Authority Question (HAQ) and Response to Question (RTQ) workflows. Results from the IND phase, highlighted in a research paper co-authored by scientists from both companies, revealed a staggering 97% reduction in time to first draft—from about 100 hours down to three—while maintaining a faithfulness to source data of approximately 95% according to the study's methodology. The HAQ and RTQ deployment has seen over 100 questions logged without any extraction errors found in the evaluated dataset, achieving a 68% average AI answer quality score against a target of 50% – 70%.

“Takeda is working to become a leader in the responsible application of AI across every area of R&D, helping our teams work more effectively and accelerate the delivery of innovative medicines to patients,” remarked Nahid Latif, Chief Regulatory Officer, Head of Global Regulatory Affairs, Takeda. “Our collaboration with Weave is an important example of this ambition in action, enabling us to implement AI-driven regulatory workflows while ensuring that regulatory professionals retain responsibility for content, verification and final decision-making.”

This partnership emerges as regulators increasingly define expectations for the responsible use of AI in drug development, emphasizing risk-based oversight, lifecycle management, validation, and human accountability. The FDA issued draft guidance on using AI to support regulatory decision-making in January 2025, followed by joint guiding principles for good AI practice from the FDA and EMA in January 2026, which prioritize human oversight. Weave and Takeda have aligned their approach with these principles, ensuring regulatory experts maintain control while AI assists with drafting, extraction, source traceability, and review support.

References:

Eser et al. Human-AI Collaboration Increases Efficiency in Regulatory Writing. arXiv. 2025. arXiv:2509.09738
Threading AI Throughout the Drug Development Lifecycle: An Enterprise Lens. Fierce Biotech webinar. Aug. 19, 2026.

About Weave Bio Weave Bio is an AI-native software company that is reshaping how novel therapies navigate the intricate journey from lab to market. The Weave platform enhances regulatory content preparation and lifecycle management for pharmaceutical companies, biotech firms, CROs, and regulatory consultants by integrating AI into every workflow step—from data extraction and authoring to review and verification—yielding compliant, submission-ready regulatory dossiers at unprecedented speeds.

Founded in 2022 and headquartered in San Francisco, Weave is supported by leading investors including USVP, Innovation Endeavors, Magnetic Ventures, Character, TMV, and Serrado Capital, and is trusted by pioneering biopharma companies worldwide. For further information, visit weave.bio and follow us on LinkedIn.